Protective effects of acidic fibroblast growth factor against cardiac arrhythmias induced by ischemia and reperfusion in rats.
An in vivo study has been conducted to evaluate the effect of acidic fibroblast growth factor (aFGF) on cardiac arrhythmias which occur in transient myocardial ischemia followed by reperfusion. In a rat model of myocardial ischemia and reperfusion, cardiac arrhythmias were assessed during the first three minutes of reperfusion. Systemic administration of 2.6 micrograms aFGF just before coronary recirculation resulted in a significant reduction in incidence and severity of ventricular extra beats (VEBs), ventricular tachycardia (VT) and ventricular fibrillation (VF), compared with control rats (VT incidence: 30% vs 80%, VF incidence: 10% vs 40%; episodes of VT: 4.1 +/- 0.34 vs 8.8 +/- 0.95; episodes of VF: 4.8 +/- 0.32 vs 11.5 +/- 1.47). Our results suggest a novel role for FGFs as potential antiarrhythmic agents.
Cuevas
P
P
Servicio de Histología, Hospital Ramón y Cajal, Madrid, Spain.
Carceller
F
F
Hernández-Madrid
A
A
Cuevas
B
B
Martínez-Coso
V
V
Giménez-Gallego
G
G
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D003326:Coronary Circulation / Q000187:drug effects; D016220:Fibroblast Growth Factor 1 / Q000494:pharmacology*; D006801:Humans; D015994:Incidence; D017202:Myocardial Ischemia / Q000503:physiopathology*; D015425:Myocardial Reperfusion; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000627:therapeutic use; D017180:Tachycardia, Ventricular / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control
D011994:Recombinant Proteins; D016220:Fibroblast Growth Factor 1